anumigilimab (CSL324) / CSL Behring - LARVOL DELTA

Effects of CSL324 in the Lung After Segmental Challenge (clinicaltrials.gov) - P1 | N=40 | Completed | Sponsor: CSL Behring | Phase classification: P1b ➔ P1

Phase classification

Effects of CSL324 in the Lung After Segmental Challenge (clinicaltrials.gov) - P1b | N=40 | Completed | Sponsor: CSL Behring | Recruiting ➔ Completed

Trial completion • ELANE • MPO

CSL324, a G-CSF receptor antagonist, blocks neutrophil migration markers that are upregulated in hidradenitis suppurativa (ISID 2023) - "Our data suggests that neutrophils contribute to HS pathophysiology and that neutrophils are increased in lesions due to an increase in G-CSF-driven migration. CSL324 counteracted G-CSF-induced transcriptomic changes and blocked neutrophil migration by reducing cell surface levels of chemokine receptors."

Dermatology • Hidradenitis Suppurativa • Inflammation • CSF3R • CXCR1

Effects of CSL324 in the Lung After Segmental Challenge (clinicaltrials.gov) - P1b | N=40 | Recruiting | Sponsor: CSL Behring | Not yet recruiting ➔ Recruiting

Enrollment open • CSF3 • ELANE • MPO

CSL324, a G-CSF receptor antagonist, blocks neutrophil migration markers that are upregulated in hidradenitis suppurativa. (PubMed, Br J Dermatol) - "Data suggest neutrophils contribute to HS pathophysiology and that neutrophils are increased in lesions due to an increase in G-CSF-driven migration. CSL324 counteracted G-CSF-induced transcriptomic changes and blocked neutrophil migration by reducing cell surface levels of chemokine receptors."

Journal • Dermatology • Hidradenitis Suppurativa • Inflammation • Pain • CSF3R • CXCR1 • ELANE • MPO

Effects of CSL324 in the Lung After Segmental Challenge (clinicaltrials.gov) - P1b | N=40 | Not yet recruiting | Sponsor: CSL Behring

New P1 trial • CSF3 • ELANE • MPO

Safety and Pharmacokinetics of Repeat Doses of CSL324 in Subjects With Hidradenitis Suppurativa and Palmoplantar Pustulosis (clinicaltrials.gov) - P1 | N=39 | Completed | Sponsor: CSL Behring | Active, not recruiting ➔ Completed

Trial completion • Dermatology • Hidradenitis Suppurativa • Immunology • Psoriasis

Pharmacokinetics and Safety of Subcutaneous CSL324 in Healthy Japanese and White Subjects (clinicaltrials.gov) - P1; N=32; Completed; Sponsor: CSL Behring; Recruiting ➔ Completed

Clinical • Trial completion

Pharmacokinetics and Safety of Subcutaneous CSL324 in Healthy Japanese and White Subjects (clinicaltrials.gov) - P1; N=32; Recruiting; Sponsor: CSL Behring; Trial completion date: Jul 2021 ➔ Oct 2021; Trial primary completion date: Jul 2021 ➔ Oct 2021

Clinical • Trial completion date • Trial primary completion date

Safety and Pharmacokinetics of Repeat Doses of CSL324 in Subjects With Hidradenitis Suppurativa and Palmoplantar Pustulosis (clinicaltrials.gov) - P1; N=40; Recruiting; Sponsor: CSL Behring; Trial completion date: Apr 2022 ➔ Nov 2022; Trial primary completion date: Apr 2022 ➔ Nov 2022

Clinical • Trial completion date • Trial primary completion date • Dermatology • Hidradenitis Suppurativa • Immunology • Neutropenia • Psoriasis

Safety and Pharmacokinetics of Repeat Doses of CSL324 in Subjects With Hidradenitis Suppurativa and Palmoplantar Pustulosis (clinicaltrials.gov) - P1; N=40; Recruiting; Sponsor: CSL Behring; Trial completion date: Jul 2021 ➔ Apr 2022; Trial primary completion date: Jul 2021 ➔ Apr 2022

Clinical • Trial completion date • Trial primary completion date • Dermatology • Hidradenitis Suppurativa • Immunology • Neutropenia • Psoriasis

Pharmacokinetics and Safety of Subcutaneous CSL324 in Healthy Japanese and White Subjects (clinicaltrials.gov) - P1; N=32; Recruiting; Sponsor: CSL Behring; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open

CSL324 in COVID-19 (clinicaltrials.gov) - P2; N=0; Withdrawn; Sponsor: CSL Behring; Not yet recruiting ➔ Withdrawn

Clinical • Trial withdrawal • Infectious Disease • Novel Coronavirus Disease

Pharmacokinetics and Safety of Subcutaneous CSL324 in Healthy Japanese and White Subjects (clinicaltrials.gov) - P1; N=32; Not yet recruiting; Sponsor: CSL Behring

Clinical • New P1 trial

CSL324 in COVID‑19 (clinicaltrials.gov) - P2; N=124; Not yet recruiting; Sponsor: CSL Behring

Clinical • New P2 trial • Infectious Disease • Novel Coronavirus Disease

Safety and Pharmacokinetics of Repeat Doses of CSL324 in Subjects With Hidradenitis Suppurativa and Palmoplantar Pustulosis (clinicaltrials.gov) - P1; N=40; Recruiting; Sponsor: CSL Behring; Active, not recruiting ➔ Recruiting

Enrollment open • Dermatology • Dermatopathology • Hidradenitis Suppurativa • Immunology • Neutropenia • Psoriasis

Safety and Pharmacokinetics of Repeat Doses of CSL324 in Subjects With Hidradenitis Suppurativa and Palmoplantar Pustulosis (clinicaltrials.gov) - P1; N=40; Active, not recruiting; Sponsor: CSL Behring; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed

Safety and Pharmacokinetics of Repeat Doses of CSL324 in Subjects With Hidradenitis Suppurativa and Palmoplantar Pustulosis (clinicaltrials.gov) - P1; N=40; Recruiting; Sponsor: CSL Behring; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open

Safety and Pharmacokinetics of Repeat Doses of CSL324 in Subjects With Hidradenitis Suppurativa and Palmoplantar Pustulosis (clinicaltrials.gov) - P1; N=40; Not yet recruiting; Sponsor: CSL Behring

Clinical • New P1 trial